P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In

News Categories

 

 

 

FDA Agrees to Review 9-Valent HPV Vaccine

Vaccinations prevent precancers in phase III study (February 20)

The biologics license application (BLA) for V503, an investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the FDA.

In November 2013, the vaccine’s developer (Merck) announced that vaccination with V503 had prevented approximately 97% of cervical, vaginal, and vulvar precancers caused by HPV types 31, 33, 45, 52, and 58 in a pivotal phase III efficacy study. V503 also generated immune responses to HPV types 6, 11, 16, and 18 that were non-inferior to those generated by Merck’s Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant).

V503 includes five more HPV types (31, 33, 45, 52, and 58) in addition to the four HPV types (6, 11, 16, and 18) in Gardasil.

Sources: Merck; February 20, 2014; and Merck; November 4, 2013.

More stories